Bioventus Inc. (NASDAQ:BVS) Receives $14.00 Average Price Target from Brokerages

Bioventus Inc. (NASDAQ:BVS) has earned an average recommendation of “Buy” from the five research firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $14.00.

Several research analysts have recently weighed in on BVS shares. CJS Securities started coverage on shares of Bioventus in a report on Friday, March 27th. They issued a “market outperform” rating and a $14.00 price target on the stock. Craig Hallum upped their price target on shares of Bioventus from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Friday, March 6th. Cantor Fitzgerald raised shares of Bioventus to a “strong-buy” rating in a report on Wednesday, March 4th. Finally, Barrington Research upped their price target on shares of Bioventus from $13.00 to $14.00 and gave the stock an “outperform” rating in a report on Friday, March 6th.

Insider Buying and Selling at Bioventus

In other news, Director Michelle Mcmurry-Heath sold 12,000 shares of the company’s stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $8.79, for a total value of $105,480.00. Following the transaction, the director owned 44,997 shares of the company’s stock, valued at approximately $395,523.63. This represents a 21.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 33.00% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BVS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Bioventus by 7.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock worth $211,000 after acquiring an additional 1,538 shares in the last quarter. Goldman Sachs Group Inc. grew its position in Bioventus by 19.1% in the first quarter. Goldman Sachs Group Inc. now owns 162,412 shares of the company’s stock worth $1,486,000 after acquiring an additional 26,103 shares in the last quarter. Legal & General Group Plc grew its position in Bioventus by 100.9% in the second quarter. Legal & General Group Plc now owns 71,409 shares of the company’s stock worth $473,000 after acquiring an additional 35,873 shares in the last quarter. Rhumbline Advisers grew its position in Bioventus by 20.6% in the second quarter. Rhumbline Advisers now owns 65,093 shares of the company’s stock worth $431,000 after acquiring an additional 11,133 shares in the last quarter. Finally, Marshall Wace LLP grew its position in Bioventus by 32.5% in the second quarter. Marshall Wace LLP now owns 211,695 shares of the company’s stock worth $1,401,000 after acquiring an additional 51,951 shares in the last quarter. 62.94% of the stock is currently owned by hedge funds and other institutional investors.

Bioventus Trading Up 5.0%

Shares of BVS stock opened at $10.68 on Friday. The stock has a market capitalization of $888.04 million, a price-to-earnings ratio of 32.36 and a beta of 0.72. Bioventus has a 1 year low of $5.81 and a 1 year high of $10.76. The company’s fifty day simple moving average is $9.23 and its two-hundred day simple moving average is $8.16. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.70 and a quick ratio of 1.19.

Bioventus (NASDAQ:BVS) last released its quarterly earnings results on Thursday, March 5th. The company reported $0.24 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.02. The firm had revenue of $157.90 million for the quarter. Bioventus had a net margin of 4.00% and a return on equity of 28.88%. Bioventus has set its FY 2026 guidance at 0.730-0.770 EPS. As a group, analysts anticipate that Bioventus will post 0.76 earnings per share for the current year.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.